| 摘要: |
| 目的：研究参芪扶正注射液辅助化疗方案对胃癌患者血清可溶性细胞间黏附分子-1（soluble intercellular adhesion molecule-1，sICAM-1）、细胞角蛋白18（cytokeratin 18，CK18）、基质金属蛋白酶-9（matrix metallopeptidase-9，MMP-9）水平的影响。方法：选取胃癌患者88 例，将其以密封信封抽签法分为治疗组和对照组，每组各44 例。对照组予以FOLFOX6化疗方案，治疗组在对照组基础上加用参芪扶正注射液治疗，2组均治疗18周，比较2组血清sICAM-1、CK18、MMP-9水平，免疫功能（CD3+、CD4+、CD8+、CD4+/CD8+），毒副作用，并评价临床疗效。结果：总有效率治疗组为75.00%（33/44），对照组为52.27%（23/44），2组比较，差异有统计学意义（P＜0.05）。治疗后，2组血清sICAM-1、CK18、MMP-9水平和CD3+、CD4+、CD8+、CD4+/CD8+水平治疗前后组内比较及治疗后组间比较，差异均有统计学意义（P＜0.05）。毒副作用发生率治疗组为11.36%（5/44），对照组为15.91%（7/44），2组比较，差异无统计学意义（P＞0.05）。结论：参芪扶正注射液辅助化疗可显著提升胃癌患者疗效，负向调控血清sICAM-1、CK18、MMP-9水平，改善免疫功能，值得临床推广应用。 |
| 关键词: 胃癌 参芪扶正注射液 化疗 可溶性细胞间黏附分子-1 细胞角蛋白18 基质金属蛋白酶-9 |
| DOI： |
|
|
| Effect of Shenqi Fuzheng injection as adjuvant therapy for chemoradiotherapy regimen on the serum levels of soluble intercellular adhesion molecule-1，cytokeratin-18，and matrix metallopeptidase-9 in patients with gastric cancer |
| LIU Xianglin,ZHANG Xiangyang |
| (Department of Traditional Chinese Medicine，Taixing People’s Hospital，Taixing 225400，Jiangsu，China) |
| Abstract: |
| Objective：To investigate the effect of Shenqi Fuzheng injection as adjuvant therapy for chemoradiotherapy regimen on the serum levels of soluble intercellular adhesion molecule-1 (sICAM-1)，cytokeratin 18 (CK18)，and matrix metallopeptidase-9 (MMP-9) in patients with gastric cancer.Methods: A total of 88 patients with gastric cancer were enrolled and divided into treatment group and control group using the sealed envelope method，with 44 patients in each group.The patients in the control group received FOLFOX6 chemoradiotherapy regimen，while those in the treatment group received Shenqi Fuzheng injection in addition to the treatment in the control group，and the course of treatment was 18 weeks for both groups.The two groups were compared in terms of the serum levels of sICAM-1，CK18，and MMP-9，immune function (CD3+，CD4+，CD8+，and CD4+/CD8+)，and toxic and side effects，and clinical outcome was assessed for both groups.Results: There was a significant difference in overall response rate between the treatment group and the control group ［75.00% (33/44) vs 52.27% (23/44)，P < 0.05］.After treatment，both groups had significant changes in the serum levels of sICAM-1，CK18，and MMP-9 and the levels of CD3+，CD4+，CD8+，and CD4+/CD8+，and there were significant differences in these indicators between the two groups after treatment (P < 0.05).There was no significant difference in the incidence rate of toxic and side effects between the treatment group and the control group ［11.36% (5/44) vs 15.91% (7/44)，P > 0.05］.Conclusion: Shenqi Fuzheng injection as adjuvant therapy for chemoradiotherapy regimen can significantly improve the treatment outcome of patients with gastric cancer，negatively regulate the serum levels of sICAM-1，CK18，and MMP-9，and improve immune function，and therefore，it holds promise for clinical application. |
| Key words: gastric cancer Shenqi Fuzheng injection chemotherapy soluble intercellular adhesion molecule-1 cytokeratin18 matrix metallopeptidase-9 |
